We further validate the findings in human CRC, where treatment with a USP7 inhibitor suppresses growth in both patient-derived organoids (PDOs) and xenografts carrying APC-truncating mutations, supporting the notion that USP7 can be used as a tumor-specific drug target for APC-mutated CRCs by suppressing WNT signaling. This evidence concerns the gene USP7 and neoplasm.